Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference
Emergent BioSolutions announced that members of its senior management team will participate in the upcoming Jefferies Global Healthcare Conference in London.
Stocks · News reference
Erste Group Research Analysts Comment on Mayr-Melnhof Packaging Divestiture
Analysts from Erste Group Research issued a positive assessment regarding Mayr-Melnhof Karton's agreement to sell 70 percent of its packaging business to KPS Capital Partners.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Erste Group Bank AG Appointed as Joint Lead-Manager for NLB d.d. Subordinated Note Issuance
Erste Group Bank AG has been mandated as a Joint Lead-Manager to organize fixed-income meetings for a potential issuance of Additional Tier 1 subordinated notes by Nova Ljubljanska banka d.d.
Erste Group and Erste Bank Polska Invest in Innovate PL FoF
Erste Group Bank AG and its subsidiary Erste Bank Polska S.A. have announced a joint investment in the Innovate PL FoF program to support private equity, private debt, and venture capital funds.
Emergent BioSolutions Receives $22.3 Million Anthrax Vaccine Contract Modification
Emergent BioSolutions has secured a contract modification from the U.S. Department of Defense valued at up to $22.3 million to supply its BioThrax vaccine.
Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
Emergent BioSolutions updated its full-year 2026 revenue guidance to $600-645 million amid competitive pressures in its commercial drug business. The company is implementing $40 million in annualized cost-cutting measures and expanding international medical countermeasures sales to 13 countries. While NARCAN faces pricing pressure and market competition, it maintains its leading market position. Management is focusing on operational efficiency, debt reduction, and pipeline execution to support long-term recovery.